Protara TherapeuticsTARA
$2.5+3.7%11월 13일 종가 기준
시가총액 $0.2B
3달 전보다 -38.4%
최고 $4.32최저 $2.13
세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요
매수 의견AI 점수 82 / 100
희귀질환과 암 환자를 위한 혁신적인 표적 치료제를 발굴 및 개발해요.
Protara Therapeutics is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. They were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in order to create new development opportunities. The company prioritizes creativity, diverse perspectives, integrity and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options.
진행 중인 임상과 AI 예측
- Phase 2TARA-002 고위험 비근침습 방광암 방광 내 주입 임상모집 중Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer81%
- Phase 3TARA-002 비근침습성 방광암 국소 주입 치료 임상모집 중Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer66%
- Phase 2염화콜린 정맥주사 장부전 환자 영양공급 임상모집 중Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support70%
- Phase 2TARA-002 소아 림프관 기형 낭종 내 주입 치료 임상모집 중Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age75%
- Phase 1TARA-002 비근침습성 방광암 주입 치료 임상 1a상완료Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)50%
- Phase 1TARA-002 고위험 비근침습 방광암 1b상 임상완료Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)45%
- Phase ?정맥 영양 공급 환자의 간질환 유병률 연구완료Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition59%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.
최근 이벤트
- 기술 수출11월 6일지켜볼 이벤트
프로타라가 노벡스로부터 TARA-002 제조 자산을 875만 달러에 인수했어요.